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ABSTRACT: Hydrolytic reactions constitute an important pathway of drug metabolism and a significant route of prodrug
activation. Many ophthalmic drugs and prodrugs contain ester groups that greatly enhance their permeation across several
hydrophobic barriers in the eye before the drugs are either metabolized or released, respectively, via hydrolysis. Thus, the
development of ophthalmic drug therapy requires the thorough profiling of substrate specificities, activities, and expression levels of
ocular esterases. However, such information is scant in the literature, especially for preclinical species often used in ophthalmology
such as rabbits and pigs. Therefore, our aim was to generate systematic information on the activity and expression of
carboxylesterases (CESs) and arylacetamide deacetylase (AADAC) in seven ocular tissue homogenates from these two species. The
hydrolytic activities were measured using a generic esterase substrate (4-nitrophenyl acetate) and, in the absence of validated
substrates for rabbit and pig enzymes, with selective substrates established for human CES1, CES2, and AADAC (D-luciferin methyl
ester, fluorescein diacetate, procaine, and phenacetin). Kinetics and inhibition studies were conducted using these substrates and,
again due to a lack of validated rabbit and pig CES inhibitors, with known inhibitors for the human enzymes. Protein expression
levels were measured using quantitative targeted proteomics. Rabbit ocular tissues showed significant variability in the expression of
CES1 (higher in cornea, lower in conjunctiva) and CES2 (higher in conjunctiva, lower in cornea) and a poor correlation of CES
expression with hydrolytic activities. In contrast, pig tissues appear to express only CES1, and CES3 and AADAC seem to be either
low or absent, respectively, in both species. The current study revealed remarkable species and tissue differences in ocular hydrolytic
enzymes that can be taken into account in the design of esterase-dependent prodrugs and drug conjugates, the evaluation of ocular
effects of systemic drugs, and in translational and toxicity studies.
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■ INTRODUCTION
Hydrolysis plays a vital role in the metabolism or activation of
many clinical (pro)drugs, such as cancer therapeutics, opioids,
and angiotensin-converting enzyme inhibitors, as well as in lipid
hydrolysis and the elimination of potentially toxic xeno-
biotics.1−3 Among many hydrolytic enzymes, carboxylesterases
(CES, E.C. 3.1.1.1) are a group of serine hydrolases that cleave
esters, amides, thioesters, and carbamates in numerous tissues
including liver, kidney, intestine, placenta, heart, brain, and
eye.4−8 So far, six human, about 20 rodent [including eight
Ces1 (Ces1a−h), eight Ces2 (Ces2a−h), two Ces3 (Ces3a−b),
and one each of Ces4 and Ces5 isoforms],9,10 three pig, and
four rabbit CES proteins have been annotated in the Uniprot
database (https://www.uniprot.org/uniprot/?query=
CES&sort=score). Among the five functional human CES
enzymes, CES1, and CES2 isoforms are the best-studied and
major drug-metabolizing enzymes.11−13 In addition, CES1 is a
major lipid-hydrolyzing enzyme.3 CES1 and CES2 share
moderate sequence homology (47%) and display unique
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substrate specificities (Table 1).2,11 In a nutshell, substrates
with a large acyl group and a small alcohol group are preferably
metabolized by CES1. In contrast, CES2 prefers substrates with
a small acyl and a large alcohol moiety.
CES1 and CES2 are widely expressed in various tissues of
multiple species. CES1 is the major hepatic CES isoform but is
also present in the lungs, heart, and adipose tissue, while CES2
is quite abundant in the intestine but also expressed in the
kidney, liver, adrenal, and stomach.9 The poorly studied CES3
isoform is expressed in the colon, brain, and at lower levels in
the liver. It has much lower activity than CES1 or CES2 but
may participate in irinotecan hydrolysis and in lipolysis in
adipocytes.16,19,22−24 The metabolic roles of CES4 and CES5
are unknown, but they are expressed in neuronal cells.25−27
CES6 is present in human and mouse cerebellums and is
speculated to take part in detoxification within the neural
system.28 Arylacetamide deacetylase (AADAC)16 is another
serine hydrolase and has recently emerged as an important
drug-metabolizing enzyme with a substrate specificity over-
lapping with CESs. It is known to prefer substrates with the
smallest acyl moieties (Table 1).29 The expression of human,
rat, mouse, cynomolgus monkey, and dog AADAC has been
found in the liver, kidney, and intestine.27,29
The eye is a complex organ composed of multiple cell types
in the anterior (conjunctiva, cornea, iris ciliary body, aqueous
humor, and lens) and posterior segments (vitreous humor,
retina, retinal pigment epithelium (RPE), choroid, and
sclera).30 However, their capacity for drug metabolism is not
very well understood.31 The ocular hydrolysis of ester prodrugs
has been reported in various species. Examples include the
conversion of dipivefrin to epinephrine32,33 and the hydrolysis
of latanoprost34 in rabbit corneal homogenates, and increases in
the ocular bioavailability of pilocarpine,35 timolol,36 and
ganciclovir by utilizing their ester prodrugs37,38 in corneal and
choroidal tissues. Likewise, the cleavage of the carboxylic ester
moiety of loteprednol etabonate in rabbit cornea, aqueous
humor, and iris−ciliary body highlights the presence and
activity of esterases in these tissues.39 The hydrolysis of
nonspecific esterase substrates such as 4-nitrophenyl acetate
(NPA) and naphthyl acetate has been observed in multiple
rabbit and bovine ocular tissue homogenates.8,22,32,37,40,41
However, the enzymes responsible for these activities have
not been characterized beyond the determination of kinetic
parameters in a few cases.32 A review on global proteomics
studies42 indicated that CES1 is detectable in most human
ocular tissues except aqueous humor but quantitative
expression data is nonexistent, and information on CES
expression in other species is lacking, hampering translational
studies. Finally, there is no knowledge on the ocular expression
and activity of AADAC in the literature.43 To understand the
biotransformation capacity in the eye and the risk of the
formation of toxic metabolites from extended drug exposure
from ocular implants, the metabolic profiling of individual
ocular tissues in all preclinical species and in humans is crucial.
A more detailed characterization of the catalytic and expression
properties of ocular esterases is also important in the design of
ophthalmic (pro)drugs and drug conjugates and in under-
standing the hydrolysis of drugs entering the eye from the
systemic circulation.
Therefore, we aimed to characterize the activities and protein
expression of CES1, CES2, and CES3 isoforms and AADAC
that are metabolically active among mammalian species.
Because of the unavailability of recombinant CES enzymes
and the lack of information on their substrate selectivity in
rabbits and pigs, multiple substrates characterized for the
corresponding human CES enzymes were used. Kinetic and
inhibition studies in select tissues with the highest activities
were conducted. Finally, we performed a quantitative targeted
proteomic analysis of the tissues to provide a systematic analysis
of ocular hydrolytic enzymes in these two common preclinical
species.
■ MATERIALS AND METHODS
Chemicals and Reagents for Enzymatic Assays. 4-
Nitrophenyl acetate (NPA), 4-nitrophenol, acetonitrile (ACN),
fluorescein diacetate (FDA), D-luciferin, Bio-Rad protein assay
dye reagent (# 500-0006), diltiazem hydrochloride (purity
≥99%), timolol maleate salt (≥98%), verapamil hydrochloride
(≥99%), fluorescein, bovine serum albumin (BSA), phenyl-
methylsulfonyl fluoride (PMSF), protease inhibitor cocktail
(#P8340), phenacetin, p-phenetidine (≥99.9%), acetamino-
phen, procainamide-HCl (≥98%), procaine-HCl (>97%), p-
aminobenzoic acid (PABA), potassium phosphate buffer
(PBS), and dimethyl sulfoxide (DMSO; ≥99.9%) were
purchased from Sigma-Aldrich Finland Oy (Espoo, Finland).
Dulbecco’s phosphate-buffered saline (10 × DPBS; #
14200166) and phosphate-buffered saline (PBS) were obtained
from Thermo Fisher. Luciferin methyl ester (DME) was
purchased from the AAT bioquest (Sunnyvale, CA).
QuantiLum recombinant luciferase (rLuciferase) was from
Promega (Madison, WI). Digitonin (≥99%) was purchased
from Merck Life Science (Merck KGaA, Darmstadt, Germany).
All other chemicals were at least analytical grade.
Chemicals and Reagents for Targeted Proteomics.
Synthetic stable isotope-labeled (SIL) peptides (SpikeTi-
des_TQL) that are isotopically labeled and quantified (Table
2) were obtained from JPT Peptide Technologies GmbH
(Berlin, Germany). Guanidine hydrochloride, sodium hydrox-
ide, dithiothreitol (DTT), ammonium hydrocarbonate, iodoa-
cetamide, chloroform, methanol, MS-grade ACN, formic acid,
sodium-EDTA, Trizma (Tris base), and all other chemicals and
reagents were from Sigma (Saint Louis, MO). ProteaseMAX,
sequencing-grade lysyl endopeptidase LysC, TPCK-treated
trypsin, and urea were from Promega (Madison, WI). Solid
phase extraction (SPE) cartridges were Strata-X, 33 μm,
polymeric reversed phase (Part # 8B-S100-AAK) (10 mg/
mL) purchased from Phenomenex (Torrance, CA).
Extraction and Homogenization of Ocular Tissues. Pig
eyes were obtained from a local slaughterhouse (Lankamainen,
Kuopio, Finland). The pig eyes were removed, cooled
immediately on ice, and kept on ice during transportation to
the laboratory. The delay from eye removal to receipt at the
Table 1. Examples of Drugs Metabolized by CES and AADAC Enzymes
enzyme drug substrates selective probe substrate references
CES1 imidapril, enalapril, meperidine, oseltamivir, clopidogrel, heroin, lidocaine, irinotecan, cocaine D-luciferin methyl ester (DME) 12−16
CES2 prasugrel, irinotecan, capecitabine fluorescein diacetate (FDA), procaine 14, 16, and 17
AADAC rifabutin, rifampicin, indiplon, rifapentine, flutamide phenacetin 16 and 18−21
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c01154
Mol. Pharmaceutics 2021, 18, 1305−1316
1306
laboratory was maximally 2−3 h. Eyes from female Dutch-
belted pigmented rabbits (Linköpings Kaninfarm, Sweden) and
9 week old Long-Evans male rats (Envigo, Netherlands) were
prepared on site. To sacrifice the lab animals, a lethal dose of 60
mg/mL pentobarbital (Mebunat; Orion Pharma, Finland) was
injected into the marginal ear vein of the animals. The studies
with lab animals were approved by the local animal welfare
committee (license # ESAVI/8621/04.10.07/2017).
Eyes were dissected essentially as before.22 Briefly, eyes were
kept in ice-cold 1 × DPBS, pH 7.4. All preparations were
performed on ice during the same day. All extraocular parts
were removed, and the aqueous humor was aspirated with a 1
mL syringe 26 G needle. After this, all anterior tissues including
conjunctiva, cornea, lens, and iris−ciliary body were separated.
From the posterior segment, the vitreous and retina were
collected and the RPE layer was scraped using a small brush
into 1 mL of 1 × DPBS. Scraping from the eyecups was done
twice to ensure complete collection of the RPE. The RPE
suspensions from individual eyes were centrifuged at 6000g for
5 min at +4 °C, and the RPE pellets were pooled. Finally, the
choroid and sclera were separated and cleaned from extraocular
tissues. Specific tissues from four rabbit or six pig eyes
constituted one individual tissue pool, and three such pools
were prepared independently. Pooling helped to obtain
sufficient material for both enzyme activities and proteomics
studies and to decrease interindividual variation among outbred
animals. All tissues were stored at −80 °C until the day of the
homogenate preparation.
CES enzymes are localized in the endoplasmic reticulum,2,45
but some activity resides in the cytoplasm.46 Therefore, to
prevent possible losses during sample preparation, we used
whole tissue homogenates to characterize CES expression and
activity in ocular tissues. The homogenization of pooled ocular
tissues in 1 × DPBS buffer (3:1 v/w) was done with a Dounce
homogenizer (Thomas Scientific; Swedesboro, NJ) with 5−10
strokes, depending on the ocular tissue. Aqueous humor and
vitreous were homogenized without adding buffer. Tissue
homogenization buffer was supplemented with protease
inhibitor cocktail without phenylmethylsulfonyl fluoride
(PMSF), a known inhibitor of esterases.47,48 After homoge-
nization, all samples were sonicated at 750 W (Vibra-Cell
VCX50 and a four-element microtip probe; Sonics & Materials
Inc., Newton, CT) using four pulses of 45 s with a cooling
interval of 15 s. After homogenization and sonication, all tissue
homogenates were centrifuged at 10 000g for 15 min at +4 °C.
Supernatants were collected, aliquoted, and stored at −80 °C as
whole tissue homogenates. Homogenates for rat whole eye
(covered by the license # ESAVI/8621/04.10.07/2017) and
human liver, kindly donated by Prof. Olavi Pelkonen, from
Oulu University Hospital,44 were also prepared as positive
controls for the enzyme assays. Protein quantification of the
homogenates was done using the Bradford assay (Bradford,
1976) and bovine serum albumin standard (0.25−2 mg/mL).
Hydrolysis Assays. 4-Nitrophenol Acetate (NPA) Hydrol-
ysis. NPA hydrolysis was performed with a slight modification
to our previous protocol22 in clear flat-bottom 96-well Thermo
Scientific Sterilin Microtiter plates at 37 °C. Diluted ocular
samples (8 μg of protein in 80 μL of PBS) were pipetted into
the reaction wells, and the background absorbance was
measured at 405 nm for 10 min of preincubation. To start
the reaction, an equal volume of NPA was added to a final
concentration of 400 μM. Changes in absorbance at 405 nm
were recorded with a Victor2 Microplate Reader (PerkinElmer
Wallac 1420, St. Paul, MN) for 45 min with 90 s reading
intervals. 4-Nitrophenol was used to generate a standard curve
(5−400 μM).
D-Luciferin Methyl Ester (DME) Hydrolysis. The hydrolysis
of DME was monitored with slight modifications using the
published bioluminescence-based assay13,21 where recombinant
firefly luciferase enzyme was used to detect the D-luciferin that
formed in the reaction mixture. The DME hydrolysis reaction
was done in white-coated 96-well plates (Thermo Scientific
Table 2. List of Peptides Used for CESs and AADAC in Multiple Speciesa
enzyme peptides sequences species (UniProt ID)
CES1 SYPIVNVSK*392 rabbit (P12337)
FWANFAR*505,503,468 human (P23141), rat (Q63108), pig (F1RF16)
CES2 NIAHFGGNPGR*194 rabbit (G1T7P3)
ADHGDELPFVFR*466 human (O00748)
AGVHTFLGIPFAK*67 rat (A0A0G2K455)







AADAC FWSEYFTTDR258,258,257 human (P22760), pig (A0A287AXR4), rat (Q9QZH8)
YPGFLDVR*318,318,317 human (P22760), pig (A0A287AXR4), rabbit (Q7M370)
TPTPGSLELAQK*309 rat (Q9QZH8)
LDVVVVSTNYR145 rabbit (Q7M370)
Na+/K+ATPase AAVPDAVGK* all species
aThe bold K/R indicate the 13C- and 15N-labeled residues required for quantitation. The number is the C-terminal residue of the peptide in the
respective protein, or when the peptide is common for multiple species, the number is for the human isoform. SpikeTides_TQL peptides were used
as internal standards. The C-terminal tetrapeptide tag on these is cleaved by the protease digestion. A peptide cocktail (20 nM each) used for
simultaneous MRM quantitation was prepared in 0.1 M ammonium bicarbonate solution and ACN (1:4). Peptides marked with an asterisk (*)
were used for protein quantitation. Note: the pig CES2 gene is absent from the reference genome [UCSC Genome Browser assembly ID:
susScr11].
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Sterilin Microtiter Plates). Tissue lysates (5 μg of protein) were
preincubated in 0.1 M PBS, pH 6.5. The reaction was initiated
by adding DME to a final concentration of 5 μM in a final
volume of 200 μL. The hydrolysis of DME was allowed to
proceed for 20 min at 37 °C. The formed D-luciferin was
quantitated by an injection of 73 μL of the luciferase detection
reagent [3 μg of rLuciferase, 50 nmol of ATP, and 50 nmol of
MgCl2 in PBS], and the luminescence was measured
immediately with a Victor2 Microplate Reader (560 nm, 1 s).
Serial 2-fold dilutions of D-luciferin in 0.1 M PBS, pH 6.5 were
used to generate the standard curve (0.156−10 μM).
Fluorescence Diacetate (FDA) Hydrolysis. A fluorometric
assay was used to determine the hydrolysis of FDA to
fluorescein.17,49 Diluted samples (5 μg of protein) were
incubated at 37 °C in black 96-well Thermo Scientific Nunc
F96 MicroWell plates. The background fluorescence was
measured with a Victor2 Microplate Reader at excitation (485
nm) and emission (535 nm) for a 5 min preincubation at 37 °C.
The reaction was started by adding FDA to a final 100 μM
concentration to each well in a 200 μL total volume.
Fluorescence readings were recorded every 60 s over 30 min.
The fluorescein stock solution was used to generate a standard
curve (0.156−10 μM) using 2-fold serial dilutions in 0.1 M
PBS, pH 7.4.
The above assays were optimized for linearity to time and
protein concentration in pilot studies, and the final organic
solvent content was 0.5% (v/v) or less. Specific activities were
calculated with the use of the standard curves, rate of the signal
change at the linear response range, and the protein
concentration. The reaction rates of blank samples (tissue
sample replaced by the buffer, substrate replaced by solvent)
were measured to control for any nonspecific hydrolysis of the
probe substrates and subtracted from sample reaction rates.
Three technical replicates were measured for each biological
tissue pool, and the mean ± standard deviation (SD) was
calculated.
Quantification of Procaine and Phenacetin Metabo-
lites by LC−MS. Procaine Hydrolysis. Procaine, a known
human CES2 substrate,2,17,50 was incubated with rabbit and pig
ocular tissues. After preincubation of the substrate (100 μM
procaine in 0.1 M Tris-HCl, pH 7.4) at 37 °C, the reaction was
initiated with tissue samples (20 μg of protein) in a total
reaction volume of 200 μL. All the samples in parallel with the
controls (no substrate or no enzyme) were incubated for 50
min at 37 °C on a shaker incubator (Heidolph Titramax 1000
platform shaker, Berlin Germany). The reaction was terminated
by adding 200 μL of ice-cold ACN containing the internal
standard procainamide (1 μM final concentration), followed by
centrifugation at 4 °C for 10 min at 10 000g. Supernatants were
collected for HPLC analysis. The standard curve was
established using the hydrolysis product PABA with the
concentration range 0.1−1000 nM.51
Phenacetin Hydrolysis. Phenacetin, a specific substrate for
human AADAC,18,19,24 was incubated with ocular tissue
homogenates. The substrate (4 mM, final concentration) was
preincubated in the 0.1 M Tris-HCl, pH 7.4, buffer at 37 °C for
5 min, after which the tissue samples (20 μg of protein) were
added to start the reaction in the total reaction volume of 200
μL. All the reaction and control samples were incubated for 50
min at 37 °C with shaking. The reaction was terminated by
adding 200 μL of ice-cold ACN containing acetaminophen at
an 1 μM final concentration as the internal standard, followed
by centrifugation at 4 °C for 10 min at 10 000g. A standard
curve using the metabolite p-phenetidine (0.1−100 μM)24 was
established. The protein amount and incubation time were
optimized from earlier pilot experiments for both procaine and
phenacetin hydrolysis reactions. All incubations were per-
formed in triplicate including the controls (control with no
sample, control with no substrate), and the data are expressed
as mean ± SD.
LC/Q Orbitrap MS Analysis. The metabolites from the above
CES2 and AADAC assays were analyzed using a Waters
(Milford, MA) Acquity ultra-performance liquid chromato-
graphic (UPLC) coupled with a Q-Exactive Focus Orbitrap MS
(Thermo Scientific). A Waters HSS T3 column (2.1 mm × 100
mm, 1.8 μm particle size) was used with elution gradients A
(0.1% formic acid) and B (methanol) [0−0.5 min, 1% B; 0.5−4
min, 1%−20% B; 4−4.5 min, 20%−98% B; 4.5−5 min, 98% B;
and 5−6 min, 98%−1% B]. The injection volume was 2 μL with
a flow rate of 0.5 mL/min and a column temperature of 40 °C.
A positive ionization mode with a capillary voltage of 3000 V
and a mass range of 70−1000 m/z was used. The mass
resolution was 35 000 (full width at half-maximum @ m/z 200)
for a full scan and 17 500 for MS/MS in data-dependent
acquisition mode. For desolvation and nebulizer, nitrogen gas
(sheat gas 40, auxiliary gas 10, and sweep gas 3 arbitrary units)
was used, the auxiliary gas temperature was 500 °C, and the
capillary temperature was 320 °C. An external calibration
system was used, and the data was processed using Thermo
Xcalibur (version 4.1.31.9; Thermo Fisher Scientific Inc.).52
Estimation of Kinetic and Inhibition Properties.
Because of their high hydrolytic activity, corneal and retinal
samples from pig and rabbit were used to determine the
apparent kinetic parameters Michaelis−Menten constant (Km)
and maximum reaction velocity (Vmax) for the hydrolysis of
NPA, FDA, and DME. At least five different substrate
concentrations within the following ranges (NPA 0.1−2 mM;
FDA 3−100 μM; DME 0.3−10 μM) were used in triplicate
using 5−8 μg of protein per well. The inhibition of the NPA,
DME, and FDA hydrolytic activities by published esterase
inhibitors (PMSF, digitonin, timolol, verapamil, and diltia-
zem)47,53−55 was conducted as described above with the
following modifications. Inhibitors were tested at a final
concentration range of 0.4−400 μM except for PMSF (0.3−
2.5 mM). The substrate concentrations were reduced to
apparent Km values samples (NPA, 0.1 mM; DME, 5 μM; FDA,
10 μM). The control samples contained solvent instead of the
inhibitor.
In all enzymatic measurements above, negligible hydrolysis
rates were observed in the blank sample incubations, which
indicated that nonenzymatic hydrolysis is minimal in the
present experimental conditions (data not shown).
Targeted Proteomics. In Silico Design of Peptides.
Protein sequences were retrieved from the UniProt database
(www.uniprot.org/help/uniprotkb). Unique peptide sequences
for each protein were designed using BLAST56 and
CLUSTALW algorithms.57 We aimed to use the peptide
sequences that were also conserved across multiple species
whenever possible. Peptides were selected according to peptide
synthesis recommendations.58 The peptide for the membrane
marker Na+/K+ ATPase was kindly provided by Dr. Mikko
Gynther at UEF (Table 2).
Sample Preparation and Trypsin Digestion. The same
samples used for enzymatic assays were used for targeted
proteomic quantification. For the denaturation, tissue samples
(50 μg of protein homogenate) were adjusted to 220 μL by
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adding solubilizer (7 M guanidine hydrochloride, 3 M Tris-HCl
pH 8.5, and 0.5 M Na2-EDTA pH 8.0) in low-protein-binding
tubes (Thermo Scientific). Then, an equal volume of DTT was
added. The samples were mixed for 60 min at room
temperature in the dark. Thereafter, a 2.5-fold excess of
iodoacetamide was added and incubated for 60 min at room
temperature in the dark to alkylate the sulfhydryl groups. For
protein precipitation, the samples were cooled on ice and ice-
cold methanol (600 μL), chloroform (150 μL), and deionized
water (450 μL) were added sequentially with mixing by
inversion. Tubes were centrifuged at 15 000g for 5 min at +4
°C. The upper layer containing lipids was discarded, and the
samples were washed twice by ice-cold methanol (450 μL). The
remaining protein pellets were resuspended by adding 6 M urea
(9 μL) and 0.1 M Tris-HCl (36.5 μL) and mixing for 10 min at
room temperature.
To ensure complete resuspension, intermittent sonication
was done (30 s per cycle: Branson 2510) while keeping samples
on ice. For the protein digestion, 0.5 μg of LysC (1/100-fold of
protein amount) and proteaseMax (final concentration 0.05%)
were added to the samples processed above. Subsequently, 0.15
pmol of heavy-labeled peptides (Table 2) were added to each
50 μg protein sample tube and incubated for 3 h at 37 °C.
Thereafter, TPCK-treated trypsin (0.5 μg) was added to each
tube and incubated overnight at 37 °C. The digestion was
terminated by adding 3 μL of 20% formic acid per sample,
followed by centrifugation at 15 000g at +4 °C. The
supernatants were transferred to fresh vials, and an aliquot
corresponding to 22.7 μg of original protein homogenate from
each digest was taken for targeted quantitative proteomic
analysis. The digests were treated with SPE (C18, 10 mg/mL
cartridges) in preparation for nanoLC−MS/MS analysis.
Cartridges were conditioned with 250 μL of methanol followed
by 250 μL of deionized water. A sample was added, and the
cartridges were washed with 150 μL of deionized water.
Peptides were eluted with 250 μL of ACN/0.1% formic acid
(60/40) into 0.5 mL LoBind Eppendorf tubes. Samples were
then evaporated to dryness and reconstituted in 50 μL of 2%
ACN. The samples were centrifuged at 13 400g for 5 min, and
the supernatants were transferred to deactivated vial inserts for
analysis.
Targeted Quantitative Analysis with NanoLC−MS/
MS. The analysis was performed as previously described59,60 on
a nanoAcquity (Waters) coupled to a QTRAP 5500 with a
NanoSpray III source (SCIEX, Framingham, MA). The system
control was with nanoAcquity UPLC Console software
(Waters) and Analyst 1.5 (SCIEX). The mobile phase was as
follows: A, 1% ACN and 0.1% formic acid in deionized water
and B, 100% ACN. The injection volume was 0.2 μL
corresponding to 0.091 μg of sample or 0.4% of the nominal
sample amount (22.7 μg). A sample was loaded onto a
Symmetry C18 trap column (Waters, part # 186006527, 5 μm
particle size, 180 μm × 20 mm). The trapping flow was 15 μL/
min of mobile phase A for 1 min. The analytical column was a
BEH130 C18, 1.7 μm particle size, 150 mm × 100 mm (Waters,
part # 186003550). The flow rate was 1.3 μL/min, and the
gradient is shown in Table S1, with the total run time being 35
min. The mass spectrometer was operated in the positive mode
with the ion spray voltage set at 4000. A 90 s scheduled
acquisition window was used for each peptide. For a selection of
multiple reaction monitoring (MRM) transitions to be used
(two labeled and two unlabeled per peptide), a range of
transitions were first predicted by Skyline software (version 2.6,
University of Washington). The five transitions giving the
highest response for SIL peptide standards were selected, and
the collision energies were optimized by repeated injection onto
the system (declustering potentials were left unchanged). The
two MRMs giving the best response were then selected for use
in concentration calculations. MRM data was processed using
MultiQuant 2.0.2 (SCIEX). Peptide concentrations were
calculated using area ratios of endogenous (unlabeled) to a
known amount of SIL peptide standard (0.15 pmol to the initial
50 μg of protein). Equality of response between the SIL and
unlabeled peptides was assumed. One peptide, generally that
giving the highest value, was used to report the concentration of
the relevant protein with a second peptide, if available, being
used as confirmatory.
Statistical Analysis. The differences among hydrolytic
activities were analyzed by ANOVA using the SigmaPlot
software (Sigma Plot 13.0, Systat Software Inc., San Jose, CA),
followed by Mann−Whitney U test for statistical comparisons
between species and between tissues. Between species,
statistically significant differences are ranked by the asterisk
signs (in the order of *, p < 0.05; **, p < 0.01, and *** p <
0.001). Between tissues of the same species, statistically
significant differences in comparison to conjunctiva are
represented by the dagger sign (†, p < 0.05). Nonlinear
regression analysis to determine the Km, Vmax, and IC50 values
were done using GraphPad Prism (GraphPad, 5.04 Software
Inc., San Diego, CA). For IC50, logarithms of inhibitor
concentrations were plotted against the relative response (0
μM inhibitor = 100%).
■ RESULTS
NPA, DME, and FDA Hydrolytic Activities. NPA is often
used to measure the activities of various hydrolytic enzymes
including CESs, AADAC, acetylcholinesterase, and arylesterase
in multiple species.2,22,23,61 The positive controls, rat whole eye
and human liver homogenates, showed high rates of NPA
hydrolysis (Figure 1A) as expected from the literature.22,40,61
Rabbit samples showed quite similar rates of 30−45 nmol/min/
mg protein for NPA hydrolysis among most tissue homoge-
nates, while the lowest activity was observed in RPE (17.5 ± 2.7
nmol/min/mg) and the highest in the choroid (81.6 ± 6.8
nmol/min/mg). For the pig, NPA hydrolysis rates were very
similar, around 20 nmol/min/mg among all tissues, except the
lowest rate was observed again with RPE (8.4 ± 1.0 nmol/min/
mg).
Overall, the enzymatic activities in pig tissues tended to be
lower than those in the rabbit, corresponding to earlier data,22
and statistically significant species differences were noted for
the cornea, aqueous humor, and choroid.
DME has been suggested as a highly selective and sensitive
substrate for detecting CES1 activity in the human liver.13 To
date, there are no reports on DME hydrolytic activities in ocular
tissues or in other rabbit or porcine tissues. Control samples
showed the hydrolysis rates for human liver and rat whole eye
homogenate at 3.6 ± 0.7 and 2.6 ± 0.2 nmol/min/mg,
respectively (Figure 1A). In rabbit ocular tissues, hydrolysis
rates were high (≥1 nmol/min/mg) in the conjunctiva, cornea,
and choroid, moderate (0.5−1.0 nmol/min/mg) in the
aqueous humor and vitreous, and low (0.1−0.5 nmol/min/
mg) in the RPE and retina (Figure 1B). Similarly, in pig, DME
hydrolysis was high (≥1 nmol/min/mg) in the conjunctiva,
cornea, and choroid, more moderate (about 0.5−1 nmol/min/
mg) in the retina, and relatively low (0.1−0.2 nmol/min/mg)
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in the RPE, aqueous humor, and vitreous (Figure 1B).
Statistically significant species differences were noted for
aqueous humor and vitreous, which had about 5−10-fold
higher activity in the rabbit than in the pig.
FDA has been indicated as a probe substrate for the
determination of CES2 activity in human liver17,49 while its
hydrolysis has not been studied so far in ocular tissues or in
rabbit or porcine tissues. Rabbit tissues showed (Figure 1C)
high hydrolysis rates (>1.0 nmol/min/mg) in the choroid,
cornea, and conjunctiva as compared to other tissues (retina,
0.5−1 nmol/min/mg; RPE, aqueous humor and vitreous, 0.1−
0.2 nmol/min/mg). FDA hydrolysis was remarkably low in
most pig ocular tissues (<0.1 nmol/min/mg) except retinal
samples (0.6 ± 0.1 nmol/min/mg). Much higher hydrolysis
rates (up to 20-fold) were seen in most rabbit ocular tissues as
compared to porcine tissues (Figure 1C), and cornea, choroid,
and conjunctiva showed statistically significant species differ-
ences.
Procaine and Phenacetin Hydrolysis. The presence of
CES2 in ocular tissues was also probed by measuring the
formation of human CES2-selective metabolite PABA from
procaine.50,51 Rabbit ocular tissues showed PABA formation in
all tissues (Figure 2). The activities were rather similar in the
cornea, vitreous, RPE, and choroid (∼0.2−0.3 nmol/min/mg)
while the aqueous humor and conjunctiva displayed 4−7-fold
lower levels (∼0.04−0.1 nmol/min/mg). In contrast, the pig
ocular tissues showed more evenly distributed procaine
hydrolysis rates in all tissues, ranging from the lowest in
aqueous humor (0.02 nmol/min/mg) to the highest in the
retina (0.09 nmol/min/mg). Rabbit tissues tended to contain
higher rates of PABA formation as compared to pig tissues,
similarly to FDA hydrolysis.
Phenacetin is hydrolyzed to p-phenetidine by the human
AADAC.24 However, the levels of p-phenetidine formed in the
incubation from the ocular tissue of rabbit and pig were below
the detection limit (∼0.1 pmol/min/mg) in the present
experimental conditions (data not shown). The positive control
samples showed significant activities as expected.
Kinetics and Inhibition Studies. Kinetic parameters for
NPA, DME, and FDA hydrolysis were determined in pig and
Figure 1. Hydrolysis of (A) NPA, (B) DME, and (C) FDA in ocular tissue samples from pigmented rabbits (white columns), pig (gray columns), and
positive controls (patterned columns; a = rat whole eye homogenate, b = human liver homogenate). The data shown are mean ± SD from three
different pools, each measured in three technical replicates. Statistical comparisons between species (*) and between tissues in the same species as
compared to conjunctiva (†) were done by the Mann−Whitney nonparametric test. Statistically significant differences are ranked as follows: *†, p <
0.05, **, p < 0.01, ***p < 0.001.
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rabbit corneal and retinal tissues and compared to the existing
literature (Table 3 and Figure 1). For all three substrates, the
observed Km values were within 4-fold or less of the reported
values employing different human enzyme sources (Table 3).
Unfortunately, there is only limited published data on pig liver
CES1 and rabbit corneal CESs with NPA. Given the overall
similarity of the Km values across different species and tissues,
we judged that they were sufficiently accurate to select substrate
concentrations for the subsequent inhibition studies.
Inhibition studies were conducted first with the general
esterase substrate NPA to validate the hydrolysis assays (Table
4). PMSF, a generic hydrolase inhibitor, inhibited NPA
hydrolysis in pig cornea rather gradually to the maximum of
about 80% at the highest concentration. A unique IC50 value
could not be determined, but a 50% inhibition was observed at
about 200 μM (Figure 2). Under the present experimental
conditions, timolol and diltiazem could not appreciably inhibit
NPA hydrolysis (maximal inhibition of 10% and 20% at the
highest 400 μM concentration). The human CES1-selective
inhibitor digitonin showed significant inhibition of NPA
hydrolysis (∼40%) and a quantifiable IC50 value (38 ± 3 μM).
Digitonin was also used to inhibit DME hydrolysis in pig and
rabbit tissues with high DME activity. In rabbit conjunctiva,
digitonin showed no inhibition in DME hydrolysis, while a
slight 15% inhibition was observed in pig conjunctiva (Figure
3A,B). In pig and rabbit cornea, digitonin showed slightly
stronger maximal inhibitions of 45% and 30%, respectively
(Figure 3C,D). Rabbit and pig retina that showed relatively
high FDA activities were used to inhibit FDA hydrolysis using a
human CES2-selective inhibitor verapamil and timolol. No
inhibition of FDA hydrolysis was seen in pig retina for either
inhibitor (Figure 4A,B). However, about 40% inhibition of
FDA hydrolysis was evident in rabbit retina with verapamil but
less with timolol (Figure 4C,D). These data suggest that pig
and rabbit CES enzymes are somewhat affected by human CES
inhibitors, but the less than complete inhibition suggests that
multiple enzymes participate in the hydrolysis of these
substrates.
Quantification of Protein Expression. Considering the
reference samples, the human liver homogenate displayed a
higher expression of CES1 (64 ± 8 pmol/mg) as compared to
that of CES2 (30.6 ± 2.1 pmol/mg), as expected from a recent
report,65 while the expression of CES3 was very low (∼0.2
pmol/mg). We report here for the first time that the expression
of CES1 (∼3.0 pmol/mg) and CES3 (∼2.3 pmol/mg) proteins
was higher than CES2 levels (∼0.2 pmol/mg) in rat whole eye.
In rabbit ocular samples, a relatively low and even expression of
CES1 (∼0.2 pmol/mg) was seen in all tissues except
conjunctiva and choroid. CES2 was present in rabbit
conjunctiva, retina, and choroid (0.3, 0.2, and 0.1 pmol/mg,
respectively), while other tissue levels were below the lower
limit of quantitation (LLOQ, 0.1 pmol/mg protein).
Pig cornea showed the highest expression of CES1 (8.0 ± 2.5
pmol/mg), while the expression was clearly detectable in
choroid and conjunctiva (∼0.7 pmol/mg), followed by vitreous
(∼0.2 pmol/mg), and all other pig tissues were below the
LLOQ. CES2, in accordance with its absence in the pig genome
(UCSC Genome Browser assembly ID: susScr11), was not
measured in the pig tissues. Finally, CES3 showed no or very
low expression in rabbit or pig tissues, respectively, and
AADAC seemed to be absent in the ocular tissues of both
species (Table 5) in contrast to their presence in the reference
samples.56 Thus, there were clear species differences in the
expression of CES1 and CES2. CES1 was expressed at higher
levels in pig tissues as compared to the rabbit, apart from retina
and RPE where the situation was the opposite. CES2 was found
in the rabbit ocular tissues and is not believed to be present in
pig due to the absent CES2 gene.
The Na+/K+ ATPase is a membrane-bound marker58,66 that
was used to indicate the enrichment of membrane fraction in
the samples. In both rabbit and pig ocular tissues, retina and
Figure 2. Hydrolysis of procaine to PABA in ocular tissues
(conjunctiva, cornea, aqueous humor, vitreous, retina, RPE, and
choroid) of rabbit (light gray) and pig (dark gray). The data shown are
mean ± SD from three different pools, each measured in three
technical replicates. Statistical comparisons between species (*) and
between tissues in the same species as compared to vitreous (†) were
done by Mann−Whitney nonparametric test. Statistically significant
differences are ranked as follows: *, p < 0.05, **, p < 0.01, ***p <
0.001.
Table 3. Kinetics for CES Mediated Hydrolysis Reactions
substrate main enzyme Km (μM) literature data references Km(μM) (this study)
NPA multiple esterases 198 ± 17 (HLM)a 23, 32, 49, and 62 125 ± 13 in pig cornea
68 ± 15 (rabbit cornea) 263.2 ± 15 in rabbit cornea
520 ± 60 (pig liver CES1)
DME CES1 ≈5 (rhCES1) 13 2.7 ± 1.3 in pig cornea
2.5 ± 0.8 in rabbit cornea
FDA CES2 4.87 ± 0.51 (HLM) 16, 49, and 63 16 ± 1.6 in pig retina
28.8 (HLM) 5.5 ± 0.4 in rabbit cornea
aHLM, human liver microsomes; rhCES, recombinant human CES1 or CES2.
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RPE exhibited abundant expression (6−17 pmol/mg), followed
by choroid (∼4.5 pmol/mg), cornea, and conjunctiva (∼1.3
pmol/mg). The relatively cell-free aqueous humor and vitreous
had no or little Na+/K+ ATPase expression as expected. This
suggests a similar efficiency of protein extraction between all
samples.
Correlation between the Enzyme Activity and Protein
Expression. Rabbit ocular tissues showed no significant
correlation between the human CES1-related DME activity
and the quantity of CES1 protein (Figure 5A). In addition, the
selective human CES1-selective inhibitor digitonin attenuated
DME hydrolysis only by 30% in rabbit cornea or less in
conjunctiva (Table 4 and Figure 3). On the contrary, a
significant positive correlation (r2 = 0.803) was observed
between DME activity and CES1 content in pig ocular tissues
(Figure 5B). We also observed that the extent of DME
inhibition by digitonin in pig conjunctiva and cornea was
stronger than that in the rabbit (Table 4 and Figure 3) and
correlated with CES1 contents in these pig tissues.
No correlation was observed between the FDA activity and
CES2 quantity in rabbit ocular tissues (Figure 5C), although
the human CES2-selective inhibitor verapamil reduced FDA
hydrolysis significantly in rabbit retina (Table 4 and Figure 4),
the tissue with highest CES1 content. For the pig, the CES2
gene is absent and thus no correlation could be established. In
line with the absence of CES2, neither verapamil or another
human CES2 inhibitor timolol blocked FDA activity in pig
retina, indicating that another hydrolase is responsible for this
activity. However, FDA and procaine hydrolysis, often used to
determine human CES2-dependent activity, correlated strongly
(r2 = 0.810) in pig ocular tissues but poorly in rabbit tissues
(Figure 4D,E). Finally, the emerging esterase AADAC was
included in proteomics and enzymatic assays; the results
indicated negligible expression and activity of AADAC in ocular
tissues of both species.
■ DISCUSSION
Ocular drug metabolism is still poorly defined. Knowledge on
the presence and levels of drug-metabolizing enzymes in ocular
tissues would be essential to aid in ophthalmic drug
development and delivery. We aimed to generate data on the
drug-metabolizing capacity of hydrolyzing enzymes in ocular
tissues of rabbits and pigs, which are commonly employed
preclinical species for ocular drug development. Numerous
ocular drugs or prodrugs containing an ester or amide bond are
liable to hydrolysis in ocular tissues of various species.33,38,61,67
Table 4. Inhibition for CES Mediated Hydrolysis Reactionsa
inhibitor
main human
enzyme IC50 Ki references IC50 or extent of inhibition (this study)
PMSF most esterases 0.541 mM 0.56 mM 47, 48,
and 53
NPA: ∼200 μM in pig cornea
digitonin CES1 9.2 ± 0.4 μM (rhCES1) NA 53 and 54 NPA: 38 ± 3 μM in pig cornea
25.8 μM (rhCES1) DME: >200 μM in pig cornea, ∼30% at 200 μM in
rabbit cornea, <20% in both conjunctivas
timolol CES2 20% inhibition at 200 μM NA 2, 53, and
54
NPA: no inhibition in pig cornea
FDA: <20% inhibition in rabbit retina, no inhibition in
pig retina
verapamil CES2 > CES1 7.94 μM (rhCES2) 11.5 ± 1.20 μM (HLM) 20, 53,
and 64
NPA: 28 ± 7 μM in pig cornea;
3.84 ± 0.99 μM (rhCES2) FDA: 38 ± 8 μM in rabbit retina, no inhibition in pig
retina
diltiazem CES2 > CES1 3.98 μM (rhCES2) 2.89 ± 0.39 μM (HLM) 20, 53,
and 64
NPA: no inhibition in pig cornea
0.25 ± 0.02 μM (rhCES2)
aHLM, human liver microsomes; NA, not available; rhCES, recombinant human CES1 or CES2. Inhibition of substrate hydrolysis was done in pig
cornea for NPA, in pig and rabbit cornea and conjunctiva for DME, and in pig and rabbit retina for FDA.
Table 5. Concentrations of CESs and AADAC Proteins Determined in Rabbit and Pig Ocular Tissuesa
ocular tissues (pmol/mg protein)
reference samples (pmol/mg
protein)
enzyme species conjunctiva cornea aqueous humor vitreous retina RPE choroid rat whole eye human liver
CES1 rabbit <LLOD 0.14 ± 0.05 0.1 ± 0.03 0.2 ± 0.01 0.2 ± 0.03 0.1 ± 0.02 <LLOD 3.0 ± 0.1 64 ± 8.0
pig 0.7 ± 0.1 8.05 ± 2.5 <LLOD 0.2 ± 0.01 <LLOQ* <LLOD 0.7 ± 0.2
CES2 rabbit 0.3 ± 0.1 <LLOQ* <LLOD <LLOD 0.2 ± 0.1 <LLOD 0.1 ± 0.07 0.2 ± 0.05 30.6 ± 2.1
pig ND ND ND ND ND ND ND
CES3 rabbit <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD 2.3 ± 0.1 0.2 ± 0.09
pig <LLOD 0.1 ± 0.01 <LLOD <LLOD <LLOD <LLOQ* <LLOD
AADAC rabbit <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD 0.3 ± 0.01 0.8 ± 0.2
pig <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD <LLOD
Na+/K+ ATPase rabbit 1.5 ± 0.3 1.4 ± 0.7 <LLOD 1.1 ± 0.3 10.3 ± 1.3 6.0 ± 2.5 4.5 ± 1.3 1.5 ± 0.3 2.7 ± 0.2
pig 1.3 ± 0.1 1.4 ± 0.2 <LLOD 0.3 ± 0.1 17 ± 7.5 7.0 ± 1.7 4.0 ± 1.2
aLLOD, lower limit of detection = 3 × signal/noise ratio; LLOQ, lower limit of quantification = 0.1 pmol/mg protein; * protein detectable but not
quantifiable; ND, not done, due to absence of the CES2 gene. The protein expression levels of CES1, CES2, CES3, and AADAC were determined
in the rabbit and pig ocular tissues. Na+/K+ ATPase served as a marker for the membrane fraction. Each data point calculated in pmol/mg
presented above is the average of three pools ± SD.
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c01154
Mol. Pharmaceutics 2021, 18, 1305−1316
1312
Although esterase activity is well-presented, the detailed activity
and expression data on CES isoforms in the eye is still
ambiguous.22,40 For the first time in ocular tissues, we adopted
substrates and inhibitors that have been used to characterize
human CES13,16,25 and AADAC18,21 activities, because the
respective rabbit and pig enzymes have not been expressed in
vitro and characterized for their substrate specificity. To our
knowledge, there are no earlier reports on the quantitative
protein expression of these enzymes in rabbit and pig ocular
tissues. The accumulation of such information will help design
experiments in ocular drug metabolism and aid in the
interpretation of resulting data. Detailed knowledge of esterase
expression will assist in evaluating the feasibility of an esterase-
dependent prodrug approach, the design of esterase-cleavable
drug conjugates for ocular drug therapy, and the extent of
ocular effects of systemically administered drugs that are
substrates for hydrolytic enzymes. The species differences in
ocular drug hydrolysis also affect the design and interpretation
of translational and toxicity studies.
The hydrolysis of the general hydrolase substrate, NPA, has
been detected in ocular tissues of multiple species including pig
and rabbit.22,40,61 In a recent study22 from our laboratory, most
of the pig and albino rabbit ocular tissues displayed very similar
rates of NPA hydrolysis as what we report here. The only
exceptions were pig aqueous humor and rabbit choroid, with
slightly higher (30%) specific activities in the present study.
These modest differences are explained by our fully optimized
reaction conditions and a pigmented rabbit strain used here. A
similar study was earlier conducted with a naphthyl prodrug to
determine esterase hydrolysis in the anterior eye segment. The
relative hydrolysis rates of naphthyl prodrugs were similar to
those of our study (cornea > conjunctiva > aqueous humor).
Again, pigmented rabbits showed 10%−100% higher esterase
activity as compared to albino animals.8,40,61
In addition to this, dipivalyl epinephrine, an ester prodrug
showed a twice as large hydrolysis rate in the corneal epithelium
of pigmented rabbit as that seen in albinos.33 A ganciclovir ester
prodrug was hydrolyzed in descending order of reaction rate in
choroid, retina, and vitreous homogenates, a pattern similar to
that of NPA hydrolysis in our study.37,38 Similarly, loteprednol
etabonate was hydrolyzed more rapidly in rabbit cornea than in
aqueous humor.39 Likewise, topically applied latanoprost, an
ester prodrug, showed complete hydrolysis in rabbit cornea.34
In summary, across all studies, the cornea appeared to have the
highest and the vitreous and aqueous humor had the lowest
hydrolytic activities for different ester substrates. However, the
isoforms responsible for these reactions remain unknown.
To the best of our knowledge, scant literature is available on
the inhibition of ocular carboxylesterases. Lee reported 30%−
70% inhibition of naphthyl acetate hydrolysis in rabbit cornea,
iris−ciliary body, and aqueous humor by several cholinesterase
inhibitors at 1000 μM while p-chloromercuribenzoate and
EDTA, which are inhibitors of carboxylesterase and arylester-
ase, respectively, blocked the hydrolysis only by 10%−30%.61
Our inhibition analysis showed that the generic esterase
inhibitor PMSF blocked the NPA hydrolysis by more than
80% in pig cornea. Although a unique IC50 value could not be
determined, 50% inhibition was reached at ∼200 μM, which is
rather close to the reported IC50 value of ∼500 μM in other
tissues.47,48 The selective human CES1 inhibitor digitonin53
inhibited NPA hydrolysis in pig cornea by about 40%, while
timolol or diltiazem had little if any effect. Verapamil has been
reported to inhibit CES220,53 or both CES1 and CES2,64 and it
significantly blocked pig corneal NPA hydrolysis. Although
additional enzymes likely contributed to the hydrolysis of NPA,
these findings seem consistent with the higher expression of
CES1 enzyme in pig cornea that leads to substantial CES1
inhibition by digitonin and verapamil. The lack of inhibition by
timolol or diltiazem is in line with negligible CES2 expression in
pig cornea.
The human CES1-selective substrate DME13 was hydrolyzed
at the highest rates in rabbit and pig conjunctiva, cornea, and
choroid. However, there was a poor correlation between the
DME activity and CES1 content in rabbit tissues. On the
contrary, the extent of DME inhibition by digitonin was greater
(30%) in rabbit cornea that expressed the CES1 protein than in
conjunctiva lacking CES1. In contrast, DME activity and CES1
content correlated in pig. This finding is well supported by the
inhibition of DME hydrolysis, where digitonin showed a
stronger inhibitory effect in pig than in rabbit tissues. The rates
of human CES2-selective FDA hydrolysis were the highest in
the rabbit conjunctiva, cornea, and choroid. Again, no
correlation between FDA hydrolysis and CES2 content was
found in rabbit tissues. This hypothesis was supported by the
fact that no inhibition was shown in FDA hydrolysis by
verapamil. Poor correlations between hydrolysis rates of DME
or FDA substrates and CES1 or CES2 contents, respectively,
and less than complete blockade by inhibitors both suggest that
other hydrolytic enzymes in the rabbit ocular tissues contribute
to the metabolism of these human-selective substrates.
FDA has been suggested as a human CES2-specific
substrate,17,49 but later studies revealed that it is also hydrolyzed
by human AADAC.14,16 Subsequently, we determined the
hydrolysis of procaine, a more specific substrate for human
CES2,50 and of phenacetin for AADAC.19,24 Rabbit ocular
tissues showed a much higher activity for FDA and procaine
than the pig, which is in line with the lack of CES2 in the latter
species, while both AADAC content and phenacetin hydrolysis
were undetectable in both species’ tissues.
Recently, a global proteomics technique has revealed
proteins expressed in individual human ocular tissues42
although not quantitatively. Various human eye proteome
studies have detected CES1 in cornea, vitreous, RPE/choroid,
and retina but not in aqueous humor.42 Our quantitative data
lists all of these tissues as CES1-positive with the exception of
pig retina and pig aqueous humor (Table 4). Other global
proteomic studies conducted in pig or rabbit ocular tissues68,69
have only detected the presence of CES2 in the rabbit aqueous
humor.70 This contrasts with our studies where we could
quantify CES2 in rabbit conjunctiva, rabbit retina, and rabbit
choroid (Table 5).
Because we could not devise common peptide probes for pig
and rabbit enzymes, a caveat remains that a comparison of
absolute protein contents between these species may be biased
due to the differential properties of the peptides. However, the
use of exact quantities of heavy-labeled peptides ensures their
coelution and identical fragmentation with the endogenous
unlabeled peptide from the sample, thus allowing determination
of the protein concentration, and dilution experiments have
shown excellent linearity of the response. Therefore, an earlier
analysis of CES1 and CES2 in other species71 using separate
peptides showed only few-fold differences. Another counter-
argument can be made on the basis of the following: the
inhibition of DME hydrolysis by CES1-preferring digitonin was
much more efficient in pig than in rabbit tissues, and its
inhibition in conjunctiva was less than that in cornea. Both
Molecular Pharmaceutics pubs.acs.org/molecularpharmaceutics Article
https://dx.doi.org/10.1021/acs.molpharmaceut.0c01154
Mol. Pharmaceutics 2021, 18, 1305−1316
1313
findings match well with the rank order of the observed CES1
levels. Similarly, the genetically known lack of CES2 expression
in the pig was reflected in a negligible inhibition of FDA
hydrolysis in pig retina by verapamil, but a clear reduction of
this activity was in rabbit retina. Although not conclusive, these
explanations suggest that our comparative analysis of protein
expression was not grossly distorted by the use of separate
peptide probes.
Collectively, the poor correlation between CES levels and
marker activities and the modest extent of DME or FDA
inhibition both indicate that the expression and substrate
profiles of CES1 and CES2 differ across species. These
differences should be taken into consideration in follow-up
studies. We cannot yet exclude participation by other
hydrolyzing enzymes such as paraoxonases72 for the marker
activities we utilized. Conclusions that are more definitive
require heterologous expression of these rabbit and porcine
CES isoforms and characterization of their preferred substrates
and inhibitors in the future. Nevertheless, this study generated
fundamental knowledge about hydrolytic activities in the eye
and added to the literature on ocular metabolism in preclinical
species. The present study also employed, for the first time, a
quantitative proteomics approach to ocular tissues. Due to the
low level of proteins detected, future studies should aim to
improve the detection limit and address methods to enrich
samples to enhance enzyme quantitation.
■ CONCLUSIONS
Our study is the first to assess the metabolism of multiple
substrates and quantitative protein expression of carboxyles-
terases in rabbit and pig ocular tissues. Significant tissue and
species differences in these parameters were found: CES1 was
present in all rabbit tissues except conjunctiva and choroid,
while CES2 was expressed in these two tissues and retina. Pig
appeared to express CES1 in most ocular tissues and CES3 at
low levels in the cornea, while AADAC was absent in both
species. The enzymatic and inhibition studies suggest that, in
rabbit and pig ocular tissues, additional esterases participate in
the hydrolysis of NPA, DME, FDA, and procaine, with a greater
contribution to DME by CES1. Our findings will advance the
understanding of the ocular drug metabolism and its application
to ocular drug delivery and prodrug pharmacokinetics.
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